Abstract
The continuous growth of advanced malignancies almost universally correlates with the reactivation of telomerase. While there is still a great deal of basic and applied research to be done, telomerase remains a very attractive novel target for cancer therapeutics. In this review, we will discuss the challenges and the pros and cons of the most promising antitelomerase approaches currently being investigated.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / metabolism
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Cell Division / drug effects
-
Cell Transformation, Neoplastic
-
Drug Design
-
Enzyme Inhibitors / metabolism
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use*
-
Forecasting
-
Humans
-
Immunotherapy
-
Models, Biological
-
Neoplasms / diagnosis
-
Neoplasms / enzymology
-
Neoplasms / therapy*
-
Oligonucleotides, Antisense / pharmacology
-
RNA, Catalytic / pharmacology
-
Reverse Transcriptase Inhibitors / pharmacology
-
Telomerase / antagonists & inhibitors*
-
Telomerase / genetics
-
Telomerase / metabolism
-
Telomere / chemistry
-
Telomere / metabolism
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Oligonucleotides, Antisense
-
RNA, Catalytic
-
Reverse Transcriptase Inhibitors
-
Telomerase